Figure 3.
eGFR by acute percentage decline categories for dapagliflozin and placebo. The annual eGFR decline from week 2 to the end of treatment for (A) the dapagliflozin group and (B) the placebo group. (C) The annual eGFR decline from week 2 to the end of treatment as a function of acute changes in eGFR in the placebo and dapagliflozin group.